Skip to main content
Erschienen in: American Journal of Clinical Dermatology 3/2021

15.02.2021 | Review Article

Eczematous Drug Eruptions

verfasst von: Amy E. Blum, Susan Burgin

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Eczematous drug eruptions are a heterogenous group of skin reactions that resemble eczema both clinically and histologically. We reviewed the literature and cataloged the systemically administered medications that cause these eruptions, along with their characteristic clinical presentations. We identified three primary pathophysiologic etiologies: (1) cutaneous immunomodulation, (2) skin dehydration, and (3) delayed hypersensitivity. Notably, eczematous eruptions caused by altered immunity in the skin may be increasing in incidence as some responsible drugs, in particular biologic therapies (such as tumor necrosis factor-α and interleukin-17 inhibitors) and targeted cancer treatments (including immune checkpoint inhibitors and epidermal growth factor receptor inhibitors), become more commonly employed in clinical practice. Other notable causes of eczematous eruptions include antiviral agents for hepatitis C virus and cardiovascular medications in elderly individuals, and notable subtypes of eczematous reactions include systemic contact dermatitis and photoallergic reactions, which are also discussed. The diagnostic gold standard is drug rechallenge and most reactions may be treated effectively with emollients, topical corticosteroids, and oral antihistamines.
Literatur
1.
Zurück zum Zitat Apaydin R, Dökmeci Ş, Bayramgürler D, Yildirim G. Drug eruptions: a study including all inpatients and outpatients at a dermatology clinic of a university hospital. J Eur Acad Dermatol Venereol. 2000;14:518–20.PubMed Apaydin R, Dökmeci Ş, Bayramgürler D, Yildirim G. Drug eruptions: a study including all inpatients and outpatients at a dermatology clinic of a university hospital. J Eur Acad Dermatol Venereol. 2000;14:518–20.PubMed
2.
Zurück zum Zitat Barbaud A, Reichert-Penetrat S, Tréchot P, Jacquin-Petit MA, Ehlinger A, Noirez V, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol. 1998;139:49–58.PubMed Barbaud A, Reichert-Penetrat S, Tréchot P, Jacquin-Petit MA, Ehlinger A, Noirez V, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol. 1998;139:49–58.PubMed
3.
Zurück zum Zitat Borch JE, Andersen KE, Bindslev-Jensen C. The prevalence of acute cutaneous drug reactions in a Scandinavian university hospital. Acta Derm Venereol. 2006;86:518–22.PubMed Borch JE, Andersen KE, Bindslev-Jensen C. The prevalence of acute cutaneous drug reactions in a Scandinavian university hospital. Acta Derm Venereol. 2006;86:518–22.PubMed
4.
Zurück zum Zitat Segaert S, Hermans C. Clinical signs, pathophysiology and management of cutaneous side effects of anti-tumor necrosis factor agents. Am J Clin Dermatol. 2017;18:771–87.PubMed Segaert S, Hermans C. Clinical signs, pathophysiology and management of cutaneous side effects of anti-tumor necrosis factor agents. Am J Clin Dermatol. 2017;18:771–87.PubMed
5.
Zurück zum Zitat Cossio M-L, Genois A, Jantchou P, Hatami A, Deslandres C, McCuaig C. Skin manifestations in pediatric patients treated with a TNF-alpha inhibitor for inflammatory bowel disease: a retrospective study. J Cutan Med Surg. 2020;24(4):333–9.PubMed Cossio M-L, Genois A, Jantchou P, Hatami A, Deslandres C, McCuaig C. Skin manifestations in pediatric patients treated with a TNF-alpha inhibitor for inflammatory bowel disease: a retrospective study. J Cutan Med Surg. 2020;24(4):333–9.PubMed
6.
Zurück zum Zitat Nakamura M, Lee K, Singh R, Zhu TH, Farahnik B, Abrouk M, et al. Eczema as an adverse effect of anti-TNFα therapy in psoriasis and other Th1-mediated diseases: a review. J Dermatol Treat. 2017;28:237–41. Nakamura M, Lee K, Singh R, Zhu TH, Farahnik B, Abrouk M, et al. Eczema as an adverse effect of anti-TNFα therapy in psoriasis and other Th1-mediated diseases: a review. J Dermatol Treat. 2017;28:237–41.
7.
Zurück zum Zitat Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63:567–77.PubMed Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63:567–77.PubMed
8.
Zurück zum Zitat Al-Janabi A, Foulkes AC, Mason K, Smith CH, Grif CEM. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020;34:1440–8.PubMed Al-Janabi A, Foulkes AC, Mason K, Smith CH, Grif CEM. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020;34:1440–8.PubMed
9.
Zurück zum Zitat Esmailzadeh A, Yousefi P, Farhi D, Bachmeyer C, Cosnes J, Berenbaum F, et al. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology (Basel). 2009;219:263–7. Esmailzadeh A, Yousefi P, Farhi D, Bachmeyer C, Cosnes J, Berenbaum F, et al. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology (Basel). 2009;219:263–7.
10.
Zurück zum Zitat Soh JS, Yun WJ, Kim K-J, Won CH, Park SH, Yang D-H, et al. Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions. Inflamm Bowel Dis. 2015;21:832–9.PubMed Soh JS, Yun WJ, Kim K-J, Won CH, Park SH, Yang D-H, et al. Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions. Inflamm Bowel Dis. 2015;21:832–9.PubMed
11.
Zurück zum Zitat Ezzedine K, Visseaux L, Cadiot G, Brixi H, Bernard P, Reguiai Z. Ustekinumab for skin reactions associated with anti-tumor necrosis factor-α agents in patients with inflammatory bowel diseases: a single-center retrospective study. J Dermatol. 2019;46:322–7.PubMed Ezzedine K, Visseaux L, Cadiot G, Brixi H, Bernard P, Reguiai Z. Ustekinumab for skin reactions associated with anti-tumor necrosis factor-α agents in patients with inflammatory bowel diseases: a single-center retrospective study. J Dermatol. 2019;46:322–7.PubMed
12.
Zurück zum Zitat Afzali A, Wheat CL, Hu JK, Olerud JE, Lee SD. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis. 2014;8:480–8.PubMed Afzali A, Wheat CL, Hu JK, Olerud JE, Lee SD. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis. 2014;8:480–8.PubMed
13.
Zurück zum Zitat Garcovich S, De Simone C, Genovese G, Berti E, Cugno M, Marzano AV. Paradoxical skin reactions to biologics in patients with rheumatologic disorders. Front Pharmacol. 2019;10:282.PubMedPubMedCentral Garcovich S, De Simone C, Genovese G, Berti E, Cugno M, Marzano AV. Paradoxical skin reactions to biologics in patients with rheumatologic disorders. Front Pharmacol. 2019;10:282.PubMedPubMedCentral
14.
Zurück zum Zitat Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Ann Intern Med. 2015;164:10–22.PubMed Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Ann Intern Med. 2015;164:10–22.PubMed
15.
Zurück zum Zitat Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T, Taïeb A. Cytokine imbalance with increased production of interferon-α in psoriasiform eruptions associated with antitumour necrosis factor-α treatments. Br J Dermatol. 2009;161:1081–8.PubMed Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T, Taïeb A. Cytokine imbalance with increased production of interferon-α in psoriasiform eruptions associated with antitumour necrosis factor-α treatments. Br J Dermatol. 2009;161:1081–8.PubMed
16.
Zurück zum Zitat Succaria F, Bhawan J. Cutaneous side-effects of biologics in immune-mediated disorders: a histopathological perspective. J Dermatol. 2017;44:243–50.PubMed Succaria F, Bhawan J. Cutaneous side-effects of biologics in immune-mediated disorders: a histopathological perspective. J Dermatol. 2017;44:243–50.PubMed
17.
Zurück zum Zitat Stoffel E, Maier H, Riedl E, Brüggen M-C, Reininger B, Schaschinger M, et al. Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics. Br J Dermatol. 2018;178:1151–62.PubMed Stoffel E, Maier H, Riedl E, Brüggen M-C, Reininger B, Schaschinger M, et al. Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics. Br J Dermatol. 2018;178:1151–62.PubMed
18.
Zurück zum Zitat Conrad C, Di Domizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018;9:25.PubMedPubMedCentral Conrad C, Di Domizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018;9:25.PubMedPubMedCentral
19.
Zurück zum Zitat Ariyasu T, Tanaka T, Fujioka N, Yanai Y, Yamamoto S, Yamauchi H, et al. Effects of interferon-alpha subtypes on the TH1/TH2 balance in peripheral blood mononuclear cells from patients with hepatitis virus infection-associated liver disorders. Vitro Cell Dev Biol Anim. 2005;41:50–6. Ariyasu T, Tanaka T, Fujioka N, Yanai Y, Yamamoto S, Yamauchi H, et al. Effects of interferon-alpha subtypes on the TH1/TH2 balance in peripheral blood mononuclear cells from patients with hepatitis virus infection-associated liver disorders. Vitro Cell Dev Biol Anim. 2005;41:50–6.
20.
Zurück zum Zitat Poreaux C, Bronowicki J-P, Debouverie M, Schmutz J-L, Waton J, Barbaud A. Managing generalized interferon-induced eruptions and the effectiveness of desensitization. Clin Exp Allergy. 2014;44:756–64.PubMed Poreaux C, Bronowicki J-P, Debouverie M, Schmutz J-L, Waton J, Barbaud A. Managing generalized interferon-induced eruptions and the effectiveness of desensitization. Clin Exp Allergy. 2014;44:756–64.PubMed
21.
Zurück zum Zitat Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201:1605–13.PubMedPubMedCentral Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201:1605–13.PubMedPubMedCentral
22.
Zurück zum Zitat Reddy V, Yang EJ, Myers B, Liao W. Clinical evaluation of risankizumab-rzaa in the treatment of plaque psoriasis. J Inflamm Res. 2020;13:53–60.PubMedPubMedCentral Reddy V, Yang EJ, Myers B, Liao W. Clinical evaluation of risankizumab-rzaa in the treatment of plaque psoriasis. J Inflamm Res. 2020;13:53–60.PubMedPubMedCentral
23.
Zurück zum Zitat Napolitano M, Megna M, Fabbrocini G, Nisticò SP, Balato N, Dastoli S, et al. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition. Br J Dermatol. 2019;181:604–6.PubMed Napolitano M, Megna M, Fabbrocini G, Nisticò SP, Balato N, Dastoli S, et al. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition. Br J Dermatol. 2019;181:604–6.PubMed
24.
Zurück zum Zitat Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44:355–62.PubMed Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44:355–62.PubMed
25.
Zurück zum Zitat Caldarola G, Pirro F, Di Stefani A, Talamonti M, Galluzzo M, D’Adamio S, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther. 2020;20:665–72.PubMed Caldarola G, Pirro F, Di Stefani A, Talamonti M, Galluzzo M, D’Adamio S, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther. 2020;20:665–72.PubMed
26.
Zurück zum Zitat Munera-Campos M, Ballesca F, Richarz N, Ferrandiz C, Carrascosa JM. Paradoxical eczematous reaction to ixekizumab. J Eur Acad Dermatol Venereol. 2019;33:e40–2.PubMed Munera-Campos M, Ballesca F, Richarz N, Ferrandiz C, Carrascosa JM. Paradoxical eczematous reaction to ixekizumab. J Eur Acad Dermatol Venereol. 2019;33:e40–2.PubMed
27.
Zurück zum Zitat Reyn B, Hillary T, Gils A. Eczematous eruption after guselkumab treatment for psoriasis. JAAD Case Rep. 2019;5:973–5.PubMedPubMedCentral Reyn B, Hillary T, Gils A. Eczematous eruption after guselkumab treatment for psoriasis. JAAD Case Rep. 2019;5:973–5.PubMedPubMedCentral
28.
Zurück zum Zitat Chicharro P, Rodríguez-Jiménez P, De la Fuente H, Fraga-Fernández J, Cibrian D, Sánchez-Madrid F, et al. Mixed profile of cytokines in paradoxical eczematous eruptions associated with anti-IL-17 therapy. J Allergy Clin Immunol Pract. 2020;8:3619–21.PubMed Chicharro P, Rodríguez-Jiménez P, De la Fuente H, Fraga-Fernández J, Cibrian D, Sánchez-Madrid F, et al. Mixed profile of cytokines in paradoxical eczematous eruptions associated with anti-IL-17 therapy. J Allergy Clin Immunol Pract. 2020;8:3619–21.PubMed
29.
Zurück zum Zitat Luchsinger I, Knöpfel N, Theiler M, Claustres MB, Barbieux C, Schwieger-Briel A, et al. Secukinumab therapy for Netherton syndrome. JAMA Dermatol. 2020;156:907–11.PubMed Luchsinger I, Knöpfel N, Theiler M, Claustres MB, Barbieux C, Schwieger-Briel A, et al. Secukinumab therapy for Netherton syndrome. JAMA Dermatol. 2020;156:907–11.PubMed
30.
Zurück zum Zitat Napolitano M, Gallo L, Patruno C, Fabbrocini G, Megna M. Eczematous reaction to ixekizumab successfully treated with dupilumab. Dermatol Ther. 2020;33:e13218.PubMed Napolitano M, Gallo L, Patruno C, Fabbrocini G, Megna M. Eczematous reaction to ixekizumab successfully treated with dupilumab. Dermatol Ther. 2020;33:e13218.PubMed
31.
Zurück zum Zitat Galluzzo M, D’Adamio S, Massaro A, Piccolo A, Bianchi L, Talamonti M. Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date. Clin Cosmet Investig Dermatol. 2019;12:311–21.PubMedPubMedCentral Galluzzo M, D’Adamio S, Massaro A, Piccolo A, Bianchi L, Talamonti M. Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date. Clin Cosmet Investig Dermatol. 2019;12:311–21.PubMedPubMedCentral
32.
Zurück zum Zitat Cullison SRJ, Siegfried EC. Paradoxic eczema in infants after heart transplantation. Pediatr Dermatol. 2018;35:e29-34. Cullison SRJ, Siegfried EC. Paradoxic eczema in infants after heart transplantation. Pediatr Dermatol. 2018;35:e29-34.
33.
Zurück zum Zitat Bumbacea RS, Ghiordanescu I. Atopic dermatitis induced by systemic immunosuppression with tacrolimus-case report. Eur Ann Allergy Clin Immunol. 2013;45:109–10.PubMed Bumbacea RS, Ghiordanescu I. Atopic dermatitis induced by systemic immunosuppression with tacrolimus-case report. Eur Ann Allergy Clin Immunol. 2013;45:109–10.PubMed
34.
Zurück zum Zitat Saito R, Sawada Y, Nakamura M. Two cases of eczematous drug eruption caused by oral tacrolimus administration. Contact Dermat. 2017;77:128–30. Saito R, Sawada Y, Nakamura M. Two cases of eczematous drug eruption caused by oral tacrolimus administration. Contact Dermat. 2017;77:128–30.
36.
Zurück zum Zitat Sibaud V. Dermatologic reactions to immune checkpoint inhibitors. Am J Clin Dermatol. 2018;19:345–61.PubMed Sibaud V. Dermatologic reactions to immune checkpoint inhibitors. Am J Clin Dermatol. 2018;19:345–61.PubMed
37.
Zurück zum Zitat Chan L, Hwang SJE, Byth K, Kyaw M, Carlino MS, Chou S, et al. Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events. J Am Acad Dermatol. 2020;82:311–6.PubMed Chan L, Hwang SJE, Byth K, Kyaw M, Carlino MS, Chou S, et al. Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events. J Am Acad Dermatol. 2020;82:311–6.PubMed
38.
Zurück zum Zitat Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151:1206–12.PubMedPubMedCentral Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151:1206–12.PubMedPubMedCentral
39.
Zurück zum Zitat Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83:1255–68.PubMed Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83:1255–68.PubMed
40.
Zurück zum Zitat Bottlaender L, Amini-Adle M, Maucort-Boulch D, Robinson P, Thomas L, Dalle S. Cutaneous adverse events: a predictor of tumour response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients. J Eur Acad Dermatol Venereol. 2020;34:2096–105.PubMed Bottlaender L, Amini-Adle M, Maucort-Boulch D, Robinson P, Thomas L, Dalle S. Cutaneous adverse events: a predictor of tumour response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients. J Eur Acad Dermatol Venereol. 2020;34:2096–105.PubMed
41.
Zurück zum Zitat Gnanendran SS, Turner LM, Miller JA, Hwang SJE, Miller AC. Cutaneous adverse events of anti-PD-1 therapy and BRAF inhibitors. Curr Treat Options Oncol. 2020;21:29.PubMed Gnanendran SS, Turner LM, Miller JA, Hwang SJE, Miller AC. Cutaneous adverse events of anti-PD-1 therapy and BRAF inhibitors. Curr Treat Options Oncol. 2020;21:29.PubMed
42.
Zurück zum Zitat Lee YJ, Kim HT, Won CH, Chang SE, Lee MW, Choi JH, et al. Characterization and prognostic significance of cutaneous adverse events to anti-programmed cell death-1 therapy. J Korean Med Sci. 2019;34:e186.PubMedPubMedCentral Lee YJ, Kim HT, Won CH, Chang SE, Lee MW, Choi JH, et al. Characterization and prognostic significance of cutaneous adverse events to anti-programmed cell death-1 therapy. J Korean Med Sci. 2019;34:e186.PubMedPubMedCentral
43.
Zurück zum Zitat Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol. 2019;80:990–7.PubMed Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol. 2019;80:990–7.PubMed
44.
Zurück zum Zitat Welborn M, Kubicki SL, Garg N, Patel AB. Retrospective chart review of cutaneous adverse events associated with tremelimumab in 17 patients. Am J Clin Dermatol. 2018;19:899–905.PubMed Welborn M, Kubicki SL, Garg N, Patel AB. Retrospective chart review of cutaneous adverse events associated with tremelimumab in 17 patients. Am J Clin Dermatol. 2018;19:899–905.PubMed
45.
Zurück zum Zitat Hwang SJE, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74(455–61):e1. Hwang SJE, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74(455–61):e1.
46.
Zurück zum Zitat Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterization and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12–25.PubMedPubMedCentral Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterization and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12–25.PubMedPubMedCentral
47.
Zurück zum Zitat Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28:254–63.PubMed Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28:254–63.PubMed
48.
Zurück zum Zitat Kaunitz GJ, Loss M, Rizvi H, Ravi S, Cuda JD, Bleich KB, et al. Cutaneous eruptions in patients receiving immune checkpoint blockade: clinicopathologic analysis of the nonlichenoid histologic pattern. Am J Surg Pathol. 2017;41:1381–9.PubMedPubMedCentral Kaunitz GJ, Loss M, Rizvi H, Ravi S, Cuda JD, Bleich KB, et al. Cutaneous eruptions in patients receiving immune checkpoint blockade: clinicopathologic analysis of the nonlichenoid histologic pattern. Am J Surg Pathol. 2017;41:1381–9.PubMedPubMedCentral
49.
Zurück zum Zitat Min Lee CK, Li S, Tran DC, Zhu GA, Kim J, Kwong BY, et al. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study. J Am Acad Dermatol. 2018;79:1047–52.PubMedPubMedCentral Min Lee CK, Li S, Tran DC, Zhu GA, Kim J, Kwong BY, et al. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study. J Am Acad Dermatol. 2018;79:1047–52.PubMedPubMedCentral
50.
Zurück zum Zitat Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19:31–9.PubMedPubMedCentral Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19:31–9.PubMedPubMedCentral
51.
Zurück zum Zitat Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer. 2009;10:28–35.PubMed Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer. 2009;10:28–35.PubMed
52.
Zurück zum Zitat Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6:803–12.PubMed Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6:803–12.PubMed
53.
Zurück zum Zitat Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56:317–26.PubMed Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56:317–26.PubMed
54.
Zurück zum Zitat Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425–33.PubMed Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425–33.PubMed
55.
Zurück zum Zitat Ocvirk J, Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol. 2010;24:453–9.PubMed Ocvirk J, Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol. 2010;24:453–9.PubMed
56.
Zurück zum Zitat Štulhofer Buzina D, Martinac I, Ledić Drvar D, Čeović R, Bilić I, Marinović B. Adverse reaction to cetuximab, an epidermal growth factor receptor inhibitor. Acta Dermatovenerol Croat. 2016;24:70–2.PubMed Štulhofer Buzina D, Martinac I, Ledić Drvar D, Čeović R, Bilić I, Marinović B. Adverse reaction to cetuximab, an epidermal growth factor receptor inhibitor. Acta Dermatovenerol Croat. 2016;24:70–2.PubMed
57.
Zurück zum Zitat Wnorowski AM, de Souza A, Chachoua A, Cohen DE. The management of EGFR inhibitor adverse events: a case series and treatment paradigm. Int J Dermatol. 2012;51:223–32.PubMed Wnorowski AM, de Souza A, Chachoua A, Cohen DE. The management of EGFR inhibitor adverse events: a case series and treatment paradigm. Int J Dermatol. 2012;51:223–32.PubMed
58.
Zurück zum Zitat Barbaud A, Granel F, Waton J, Poreaux C. How to manage hypersensitivity reactions to biological agents? Eur J Dermatol. 2011;21:667–74.PubMed Barbaud A, Granel F, Waton J, Poreaux C. How to manage hypersensitivity reactions to biological agents? Eur J Dermatol. 2011;21:667–74.PubMed
59.
Zurück zum Zitat Chiu HY, Cheng YP, Jee SH, Tsai TF. Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation field. Clin Exp Dermatol. 2012;37:922–4.PubMed Chiu HY, Cheng YP, Jee SH, Tsai TF. Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation field. Clin Exp Dermatol. 2012;37:922–4.PubMed
60.
Zurück zum Zitat Lichtenberger BM, Gerber PA, Holcmann M, Buhren BA, Amberg N, Smolle V, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med. 2013;5:199ra111.PubMed Lichtenberger BM, Gerber PA, Holcmann M, Buhren BA, Amberg N, Smolle V, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med. 2013;5:199ra111.PubMed
61.
Zurück zum Zitat Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002;20:110–24.PubMed Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002;20:110–24.PubMed
62.
Zurück zum Zitat Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, Mita M. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol. 2009;4:135–42.PubMed Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, Mita M. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol. 2009;4:135–42.PubMed
63.
Zurück zum Zitat Habu M, Tohyama M, Sayama K. Two cases of eczematous eruptions caused by everolimus. J Cutan Immunol Allergy. 2019;2:135–8. Habu M, Tohyama M, Sayama K. Two cases of eczematous eruptions caused by everolimus. J Cutan Immunol Allergy. 2019;2:135–8.
64.
Zurück zum Zitat Shameem R, Lacouture M, Wu S. Incidence and risk of rash to mTOR inhibitors in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2015;54:124–32.PubMed Shameem R, Lacouture M, Wu S. Incidence and risk of rash to mTOR inhibitors in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2015;54:124–32.PubMed
65.
Zurück zum Zitat Balagula Y, Rosen A, Tan BH, Busam KJ, Pulitzer MP, Motzer RJ, et al. Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer. 2012;118:5078–83.PubMed Balagula Y, Rosen A, Tan BH, Busam KJ, Pulitzer MP, Motzer RJ, et al. Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer. 2012;118:5078–83.PubMed
66.
Zurück zum Zitat Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22:2336–47.PubMed Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22:2336–47.PubMed
67.
Zurück zum Zitat Frouin E, Sebille G, Freudenberger S, Menecier B, Quoix E, Criber B, et al. Asteatotic eczema (‘eczema craquelé’) with histopathological interface dermatitis: a new cutaneous reaction following pemetrexed. Br J Dermatol. 2012;166:1359–60.PubMed Frouin E, Sebille G, Freudenberger S, Menecier B, Quoix E, Criber B, et al. Asteatotic eczema (‘eczema craquelé’) with histopathological interface dermatitis: a new cutaneous reaction following pemetrexed. Br J Dermatol. 2012;166:1359–60.PubMed
68.
Zurück zum Zitat Hazan E, Santa E, Sahu J. Diffuse rash after the administration of carboplatin and paclitaxel: answer. Am J Dermatopathol. 2016;38:393.PubMed Hazan E, Santa E, Sahu J. Diffuse rash after the administration of carboplatin and paclitaxel: answer. Am J Dermatopathol. 2016;38:393.PubMed
69.
Zurück zum Zitat Brandt K, Schäkel K, Stölzel F, Janschek J, Ehninger G, Schaich M. Auricular oedema and dyshidrotic eczema in a patient with acute myeloid leukaemia treated with cytarabine. Case Rep Oncol. 2010;3:349–53.PubMedPubMedCentral Brandt K, Schäkel K, Stölzel F, Janschek J, Ehninger G, Schaich M. Auricular oedema and dyshidrotic eczema in a patient with acute myeloid leukaemia treated with cytarabine. Case Rep Oncol. 2010;3:349–53.PubMedPubMedCentral
70.
Zurück zum Zitat Fluhr JW, Miteva M, Primavera G, Ziemer M, Elsner P, Berardesca E. Functional assessment of a skin care system in patients on chemotherapy. Skin Pharmacol Physiol. 2007;20:253–9.PubMed Fluhr JW, Miteva M, Primavera G, Ziemer M, Elsner P, Berardesca E. Functional assessment of a skin care system in patients on chemotherapy. Skin Pharmacol Physiol. 2007;20:253–9.PubMed
71.
Zurück zum Zitat Roujeau J-C, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, et al. Telaprevir-related dermatitis. JAMA Dermatol. 2013;149:152–8.PubMed Roujeau J-C, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, et al. Telaprevir-related dermatitis. JAMA Dermatol. 2013;149:152–8.PubMed
72.
Zurück zum Zitat Patel P, Malik K, Krishnamurthy K. Cutaneous adverse events in chronic hepatitis C patients treated with new direct-acting antivirals: a systematic review and meta-analysis. J Cutan Med Surg. 2016;20:58–66.PubMed Patel P, Malik K, Krishnamurthy K. Cutaneous adverse events in chronic hepatitis C patients treated with new direct-acting antivirals: a systematic review and meta-analysis. J Cutan Med Surg. 2016;20:58–66.PubMed
73.
Zurück zum Zitat Tavakoli-Tabasi S. A Longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C. J Clin Gastroenterol. 2012;46:6. Tavakoli-Tabasi S. A Longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C. J Clin Gastroenterol. 2012;46:6.
74.
Zurück zum Zitat Vázquez-López F, Manjón-Haces JA, Pérez-Alvarez R, Pérez-Oliva N. Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment. Br J Dermatol. 2004;150:1046–7.PubMed Vázquez-López F, Manjón-Haces JA, Pérez-Alvarez R, Pérez-Oliva N. Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment. Br J Dermatol. 2004;150:1046–7.PubMed
75.
Zurück zum Zitat Patrk I, Morović M, Markulin A, Patrk J. Cutaneous reactions in patients with chronic hepatitis C treated with peginterferon and ribavirin. Dermatology. 2014;228:42–6.PubMed Patrk I, Morović M, Markulin A, Patrk J. Cutaneous reactions in patients with chronic hepatitis C treated with peginterferon and ribavirin. Dermatology. 2014;228:42–6.PubMed
76.
Zurück zum Zitat Li Z, Zhang Y, An J, Feng Y, Deng H, Xiao S, et al. Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C. J Clin Virol. 2014;60:190–5.PubMed Li Z, Zhang Y, An J, Feng Y, Deng H, Xiao S, et al. Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C. J Clin Virol. 2014;60:190–5.PubMed
77.
Zurück zum Zitat Garcias-Ladaria J, Pérez-Ferriols A, Ortega-García P, Diago M. Management of refractory telaprevir-induced dermatitis using oral corticosteroids. Actas Dermosifiliogr. 2014;105:e55-60.PubMed Garcias-Ladaria J, Pérez-Ferriols A, Ortega-García P, Diago M. Management of refractory telaprevir-induced dermatitis using oral corticosteroids. Actas Dermosifiliogr. 2014;105:e55-60.PubMed
78.
Zurück zum Zitat Cacoub P, Bourlière M, Lübbe J, Dupin N, Buggisch P, Dusheiko G, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol. 2012;56:455–63.PubMed Cacoub P, Bourlière M, Lübbe J, Dupin N, Buggisch P, Dusheiko G, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol. 2012;56:455–63.PubMed
79.
Zurück zum Zitat Carrascosa R, Capusan T-M, Llamas-Velasco M, García-Buey L, Gordillo C, Sánchez-Pérez J. High frequency of severe telaprevir-associated skin eruptions in clinical practice. Acta Derm Venereol. 2016;96:97–9.PubMed Carrascosa R, Capusan T-M, Llamas-Velasco M, García-Buey L, Gordillo C, Sánchez-Pérez J. High frequency of severe telaprevir-associated skin eruptions in clinical practice. Acta Derm Venereol. 2016;96:97–9.PubMed
80.
Zurück zum Zitat Guillot B, Blazquez L, Bessis D, Dereure O, Guilhou JJ. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma. Dermatology. 2004;208:49–54.PubMed Guillot B, Blazquez L, Bessis D, Dereure O, Guilhou JJ. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma. Dermatology. 2004;208:49–54.PubMed
81.
Zurück zum Zitat Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373:1418–28.PubMed Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373:1418–28.PubMed
82.
Zurück zum Zitat Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol. 2009;23:677–83.PubMedPubMedCentral Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol. 2009;23:677–83.PubMedPubMedCentral
83.
Zurück zum Zitat Dereure O, Raison-Peyron N, Larrey D, Blanc F, Guilhou J-J. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol. 2002;147:1142–6.PubMed Dereure O, Raison-Peyron N, Larrey D, Blanc F, Guilhou J-J. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol. 2002;147:1142–6.PubMed
84.
Zurück zum Zitat do Vale EPBM, Rodrigues CHL, Kallas FE, Fucuta PS. Eczema craquelé associated with antiviral treatment for chronic hepatitis C. An Bras Dermatol. 2017;92:436–7. do Vale EPBM, Rodrigues CHL, Kallas FE, Fucuta PS. Eczema craquelé associated with antiviral treatment for chronic hepatitis C. An Bras Dermatol. 2017;92:436–7.
85.
Zurück zum Zitat Moore MM, Elpern DJ, Carter DJ. Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Arch Dermatol. 2004;140:215–7.PubMed Moore MM, Elpern DJ, Carter DJ. Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Arch Dermatol. 2004;140:215–7.PubMed
86.
Zurück zum Zitat Shen Y, Pielop J, Hsu S. Generalized nummular eczema secondary to peginterferon alfa-2b and ribavirin combination therapy for hepatitis C infection. Arch Dermatol. 2005;141:102–3.PubMed Shen Y, Pielop J, Hsu S. Generalized nummular eczema secondary to peginterferon alfa-2b and ribavirin combination therapy for hepatitis C infection. Arch Dermatol. 2005;141:102–3.PubMed
88.
Zurück zum Zitat Heng YK, Lim YL. Cutaneous adverse drug reactions in the elderly. Curr Opin Allergy Clin Immunol. 2015;15:300–7.PubMed Heng YK, Lim YL. Cutaneous adverse drug reactions in the elderly. Curr Opin Allergy Clin Immunol. 2015;15:300–7.PubMed
89.
Zurück zum Zitat Young JWS. Cutaneous drug reactions in the elderly. Drugs Aging. 2017;34(9):655–72.PubMed Young JWS. Cutaneous drug reactions in the elderly. Drugs Aging. 2017;34(9):655–72.PubMed
90.
Zurück zum Zitat Mekić S, Jacobs LC, Gunn DA, Mayes AE, Ikram MA, Pardo LM, et al. Prevalence and determinants for xerosis cutis in the middle-aged and elderly population: a cross-sectional study. J Am Acad Dermatol. 2019;81(963–9):e2. Mekić S, Jacobs LC, Gunn DA, Mayes AE, Ikram MA, Pardo LM, et al. Prevalence and determinants for xerosis cutis in the middle-aged and elderly population: a cross-sectional study. J Am Acad Dermatol. 2019;81(963–9):e2.
91.
Zurück zum Zitat Farage MA, Miller KW, Berardesca E, Maibach HI. Clinical implications of aging skin. Am J Clin Dermatol. 2009;10:73–86.PubMed Farage MA, Miller KW, Berardesca E, Maibach HI. Clinical implications of aging skin. Am J Clin Dermatol. 2009;10:73–86.PubMed
92.
Zurück zum Zitat Joly P, Benoit-Corven C, Baricault S, Lambert A, Hellot MF, Josset V, et al. Chronic eczematous eruptions of the elderly are associated with chronic exposure to calcium channel blockers: results from a case-control study. J Invest Dermatol. 2007;127:2766–71.PubMed Joly P, Benoit-Corven C, Baricault S, Lambert A, Hellot MF, Josset V, et al. Chronic eczematous eruptions of the elderly are associated with chronic exposure to calcium channel blockers: results from a case-control study. J Invest Dermatol. 2007;127:2766–71.PubMed
93.
Zurück zum Zitat Summers EM, Bingham CS, Dahle KW, Sweeney C, Ying J, Sontheimer RD. Chronic eczematous eruptions in the aging: further support for an association with exposure to calcium channel blockers. JAMA Dermatol. 2013;149:814–8.PubMed Summers EM, Bingham CS, Dahle KW, Sweeney C, Ying J, Sontheimer RD. Chronic eczematous eruptions in the aging: further support for an association with exposure to calcium channel blockers. JAMA Dermatol. 2013;149:814–8.PubMed
94.
Zurück zum Zitat Baccino D, Merlo G, Cozzani E, Rosa GM, Tini G, Burlando M, et al. Cutaneous effects of antihypertensive drugs. G Ital Dermatol E Venereol. 2020;155:202–11. Baccino D, Merlo G, Cozzani E, Rosa GM, Tini G, Burlando M, et al. Cutaneous effects of antihypertensive drugs. G Ital Dermatol E Venereol. 2020;155:202–11.
95.
Zurück zum Zitat Yoo J, Jue M-S. Intractable pruritus with chronic eczema in an elderly patient caused by long-term intake of calcium channel blocker. Contact Dermat. 2017;77:339–40. Yoo J, Jue M-S. Intractable pruritus with chronic eczema in an elderly patient caused by long-term intake of calcium channel blocker. Contact Dermat. 2017;77:339–40.
96.
Zurück zum Zitat Summers EM, Blickenstaff NR, Coman GC, Martins TB, Hill HR, Sontheimer RD. A pilot study evaluating biomarker development for drug-induced chronic eczematous eruptions of aging individuals. Ann Transl Med. 2017;5:393.PubMedPubMedCentral Summers EM, Blickenstaff NR, Coman GC, Martins TB, Hill HR, Sontheimer RD. A pilot study evaluating biomarker development for drug-induced chronic eczematous eruptions of aging individuals. Ann Transl Med. 2017;5:393.PubMedPubMedCentral
97.
Zurück zum Zitat Özkaya E, Yazganoğlu KD. Angiotensin-converting enzyme inhibitors. In: Özkaya E, Yazganoğlu KD, editors. Adverse cutaneous drug reactions to cardiovascular drugs. London: Springer; 2014. p. 67–83. Özkaya E, Yazganoğlu KD. Angiotensin-converting enzyme inhibitors. In: Özkaya E, Yazganoğlu KD, editors. Adverse cutaneous drug reactions to cardiovascular drugs. London: Springer; 2014. p. 67–83.
98.
Zurück zum Zitat Özkaya E, Yazganoğlu KD. Angiotensin II receptor blockers. In: Özkaya E, Yazganoğlu KD, editors. Adverse cutaneous drug reactions to cardiovascular drugs. London: Springer; 2014. p. 85–92. Özkaya E, Yazganoğlu KD. Angiotensin II receptor blockers. In: Özkaya E, Yazganoğlu KD, editors. Adverse cutaneous drug reactions to cardiovascular drugs. London: Springer; 2014. p. 85–92.
99.
Zurück zum Zitat Vena GA, Cassano N, Coco V, De Simone C. Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. Immunopharmacol Immunotoxicol. 2013;35:447–50.PubMed Vena GA, Cassano N, Coco V, De Simone C. Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. Immunopharmacol Immunotoxicol. 2013;35:447–50.PubMed
100.
Zurück zum Zitat Robinson HN, Morison WL, Hood AF. Thiazide diuretic therapy and chronic photosensitivity. Arch Dermatol. 1985;121:522–4.PubMed Robinson HN, Morison WL, Hood AF. Thiazide diuretic therapy and chronic photosensitivity. Arch Dermatol. 1985;121:522–4.PubMed
101.
Zurück zum Zitat Thestrup-Pedersen K. Adverse reactions in the skin from anti-hypertensive drugs. Dan Med Bull. 1987;34(Suppl. 1):3–5.PubMed Thestrup-Pedersen K. Adverse reactions in the skin from anti-hypertensive drugs. Dan Med Bull. 1987;34(Suppl. 1):3–5.PubMed
102.
Zurück zum Zitat Church R. Eczema provoked by methyl dopa. Br J Dermatol. 1974;91:373–8.PubMed Church R. Eczema provoked by methyl dopa. Br J Dermatol. 1974;91:373–8.PubMed
103.
Zurück zum Zitat Heid E, Samsoen M, Juillard J, Eberst E, Foussereau J. Papulo-vesicular endogenous eruptions induced by methyldopa and clofibrate (author’s transl). Ann Dermatol Venereol. 1977;104:494–6.PubMed Heid E, Samsoen M, Juillard J, Eberst E, Foussereau J. Papulo-vesicular endogenous eruptions induced by methyldopa and clofibrate (author’s transl). Ann Dermatol Venereol. 1977;104:494–6.PubMed
105.
Zurück zum Zitat Krasovec M, Elsner P, Burg G. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Dermatology. 1993;186:248–52.PubMed Krasovec M, Elsner P, Burg G. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Dermatology. 1993;186:248–52.PubMed
106.
Zurück zum Zitat Feldmann R, Mainetti C, Saurat J-H. Skin lesions due to treatment with simvastatin (Zocor®). Dermatology. 1993;186:272.PubMed Feldmann R, Mainetti C, Saurat J-H. Skin lesions due to treatment with simvastatin (Zocor®). Dermatology. 1993;186:272.PubMed
107.
Zurück zum Zitat de Boer EM, Bruynzeel DP. Allergy to pravastatin. Contact Dermat. 1994;30:238. de Boer EM, Bruynzeel DP. Allergy to pravastatin. Contact Dermat. 1994;30:238.
108.
Zurück zum Zitat Salna MP, Singer HM, Dana AN. Pravastatin-induced eczematous eruption mimicking psoriasis. Case Rep Dermatol Med. 2017;2017:3418204.PubMedPubMedCentral Salna MP, Singer HM, Dana AN. Pravastatin-induced eczematous eruption mimicking psoriasis. Case Rep Dermatol Med. 2017;2017:3418204.PubMedPubMedCentral
109.
Zurück zum Zitat Jowkar F, Namazi MR. Statins in dermatology. Int J Dermatol. 2010;49:1235–43.PubMed Jowkar F, Namazi MR. Statins in dermatology. Int J Dermatol. 2010;49:1235–43.PubMed
110.
Zurück zum Zitat Gerstenblith MR, Antony AK, Junkins-Hopkins JM, Abuav R. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy. J Am Acad Dermatol. 2012;66:312–6.PubMed Gerstenblith MR, Antony AK, Junkins-Hopkins JM, Abuav R. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy. J Am Acad Dermatol. 2012;66:312–6.PubMed
111.
Zurück zum Zitat Yokoyama K, Yoshida A. Late-onset and long-term systemic dyshidrotic eczema after intravenous immunoglobulin treatment for Kawasaki disease. BMJ Case Rep. 2019;12:e229596.PubMedPubMedCentral Yokoyama K, Yoshida A. Late-onset and long-term systemic dyshidrotic eczema after intravenous immunoglobulin treatment for Kawasaki disease. BMJ Case Rep. 2019;12:e229596.PubMedPubMedCentral
112.
Zurück zum Zitat Shiraishi T, Yamamoto T. Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome. Pediatr Dermatol. 2013;30:e30–1.PubMed Shiraishi T, Yamamoto T. Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome. Pediatr Dermatol. 2013;30:e30–1.PubMed
113.
Zurück zum Zitat Brazzelli V, Grassi S, Savasta S, Ruffinazzi G, Carugno A, Barbaccia V, et al. Pompholyx of the hands after intravenous immunoglobulin therapy for clinically isolated syndrome: a paediatric case. Int J Immunopathol Pharmacol. 2014;27:127–30.PubMed Brazzelli V, Grassi S, Savasta S, Ruffinazzi G, Carugno A, Barbaccia V, et al. Pompholyx of the hands after intravenous immunoglobulin therapy for clinically isolated syndrome: a paediatric case. Int J Immunopathol Pharmacol. 2014;27:127–30.PubMed
114.
Zurück zum Zitat Sarmiento E, Micheloud D, Carbone J. Complement consumption associated with eczematous cutaneous reaction during infusions of high doses of intravenous immunoglobulin. Br J Dermatol. 2004;151:721.PubMed Sarmiento E, Micheloud D, Carbone J. Complement consumption associated with eczematous cutaneous reaction during infusions of high doses of intravenous immunoglobulin. Br J Dermatol. 2004;151:721.PubMed
116.
Zurück zum Zitat Berk-Krauss J, Lee K, Lo Sicco KI, Liebman TN. Eczematous reaction to IVIG for the treatment of dermatomyositis. Int J Womens Dermatol. 2018;4:170–3.PubMedPubMedCentral Berk-Krauss J, Lee K, Lo Sicco KI, Liebman TN. Eczematous reaction to IVIG for the treatment of dermatomyositis. Int J Womens Dermatol. 2018;4:170–3.PubMedPubMedCentral
117.
Zurück zum Zitat Lee KC, Ladizinski B. Dyshidrotic eczema following intravenous immunoglobulin treatment. Can Med Assoc J. 2013;185:E530. Lee KC, Ladizinski B. Dyshidrotic eczema following intravenous immunoglobulin treatment. Can Med Assoc J. 2013;185:E530.
118.
Zurück zum Zitat Miyamoto J, Böckle BC, Zillikens D, Schmidt E, Schmuth M. Eczematous reaction to intravenous immunoglobulin: an alternative cause of eczema. JAMA Dermatol. 2014;150:1120–2.PubMed Miyamoto J, Böckle BC, Zillikens D, Schmidt E, Schmuth M. Eczematous reaction to intravenous immunoglobulin: an alternative cause of eczema. JAMA Dermatol. 2014;150:1120–2.PubMed
119.
Zurück zum Zitat Vecchietti G, Kerl K, Prins C, Kaya G, Saurat J-H, French LE. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol. 2006;142:213–7.PubMed Vecchietti G, Kerl K, Prins C, Kaya G, Saurat J-H, French LE. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol. 2006;142:213–7.PubMed
120.
Zurück zum Zitat Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139:S1-46.PubMed Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139:S1-46.PubMed
121.
Zurück zum Zitat Özkaya-Bayazit E, Güngör H. Carbamazepine induced eczematous eruptionclinically resembling atopic dermatitis. J Eur Acad Dermatol Venereol. 1999;12:182–3.PubMed Özkaya-Bayazit E, Güngör H. Carbamazepine induced eczematous eruptionclinically resembling atopic dermatitis. J Eur Acad Dermatol Venereol. 1999;12:182–3.PubMed
122.
Zurück zum Zitat Terui T, Tagami H. Eczematous drug eruption from carbamazepine: coexistence of contact and photocontact sensitivity. Contact Dermat. 1989;20:260–4. Terui T, Tagami H. Eczematous drug eruption from carbamazepine: coexistence of contact and photocontact sensitivity. Contact Dermat. 1989;20:260–4.
123.
Zurück zum Zitat Roberts DL, Marks R. Skin reactions to carbamazepine. Arch Dermatol. 1981;117:273–5.PubMed Roberts DL, Marks R. Skin reactions to carbamazepine. Arch Dermatol. 1981;117:273–5.PubMed
124.
Zurück zum Zitat Akpinar F, Dervis E. Drug eruptions: an 8-year study including 106 inpatients at a dermatology clinic in Turkey. Indian J Dermatol. 2012;57:194–8.PubMedPubMedCentral Akpinar F, Dervis E. Drug eruptions: an 8-year study including 106 inpatients at a dermatology clinic in Turkey. Indian J Dermatol. 2012;57:194–8.PubMedPubMedCentral
125.
Zurück zum Zitat Pigatto PD, Morelli M, Polenghi MM, Mozzanica N, Altomare GF. Phenobarbital-induced allergic dermatitis. Contact Dermat. 1987;16:279. Pigatto PD, Morelli M, Polenghi MM, Mozzanica N, Altomare GF. Phenobarbital-induced allergic dermatitis. Contact Dermat. 1987;16:279.
126.
Zurück zum Zitat Sanz-Navarro J, Feal C, Dauden E. Treatment of human scabies with oral ivermectin: eczematous eruptions as a new non-reported adverse event. Actas Dermosifiliogr. 2017;108:643–9.PubMed Sanz-Navarro J, Feal C, Dauden E. Treatment of human scabies with oral ivermectin: eczematous eruptions as a new non-reported adverse event. Actas Dermosifiliogr. 2017;108:643–9.PubMed
127.
Zurück zum Zitat Nakatani K, Kurose T, Hyo T, Watanabe K, Yabe D, Kawamoto T, et al. Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus metformin. Diabetes Ther. 2012;3:14.PubMedPubMedCentral Nakatani K, Kurose T, Hyo T, Watanabe K, Yabe D, Kawamoto T, et al. Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus metformin. Diabetes Ther. 2012;3:14.PubMedPubMedCentral
128.
Zurück zum Zitat Guliani A, Yadav TC, Jha K. Type 2 diabetic female with vildagliptin associated eczematous eruption. Postgrad Med J. 2019;95:392–3.PubMed Guliani A, Yadav TC, Jha K. Type 2 diabetic female with vildagliptin associated eczematous eruption. Postgrad Med J. 2019;95:392–3.PubMed
129.
Zurück zum Zitat Sugiyama S, Tanaka R, Hayashi H, Izumi K, Nishie W, Aoyama Y. Acquired haemophilia A in DPP4 inhibitor-induced bullous pemphigoid as immune reconstitution syndrome. Acta Derm Venereol. 2020;100:adv00178.PubMed Sugiyama S, Tanaka R, Hayashi H, Izumi K, Nishie W, Aoyama Y. Acquired haemophilia A in DPP4 inhibitor-induced bullous pemphigoid as immune reconstitution syndrome. Acta Derm Venereol. 2020;100:adv00178.PubMed
130.
Zurück zum Zitat Tripathy A, Kumari KM, Babu AVM, Pai SB, Kumar DM. Anything rare is possible: letrozole induced eczematous skin eruption. J Clin Diagn Res. 2014;8:YD03-4.PubMedPubMedCentral Tripathy A, Kumari KM, Babu AVM, Pai SB, Kumar DM. Anything rare is possible: letrozole induced eczematous skin eruption. J Clin Diagn Res. 2014;8:YD03-4.PubMedPubMedCentral
131.
Zurück zum Zitat Yoshida A, Sugita K, Tani N, Yamamoto O. Correlation between serum thymus and activation-regulated chemokine levels and eczematous drug eruption following oral challenge test with clonazepam. Clin Exp Dermatol. 2020;45:1063–5.PubMed Yoshida A, Sugita K, Tani N, Yamamoto O. Correlation between serum thymus and activation-regulated chemokine levels and eczematous drug eruption following oral challenge test with clonazepam. Clin Exp Dermatol. 2020;45:1063–5.PubMed
132.
Zurück zum Zitat Harowick N, King CM. Generalized eczematous reaction to erythropoietin. Contact Dermat. 1993;28:123. Harowick N, King CM. Generalized eczematous reaction to erythropoietin. Contact Dermat. 1993;28:123.
133.
Zurück zum Zitat Salava A, Alanko K, Hyry H. Dipyridamole-induced eczematous drug eruption with positive patch test reaction. Contact Dermat. 2012;67:103–4. Salava A, Alanko K, Hyry H. Dipyridamole-induced eczematous drug eruption with positive patch test reaction. Contact Dermat. 2012;67:103–4.
134.
Zurück zum Zitat Saito-Sasaki N, Sawada Y, Nishio D, Nakamura M. First case of drug eruption due to ipragliflozin: case report and review of the literature. Australas J Dermatol. 2017;58:236–8.PubMed Saito-Sasaki N, Sawada Y, Nishio D, Nakamura M. First case of drug eruption due to ipragliflozin: case report and review of the literature. Australas J Dermatol. 2017;58:236–8.PubMed
135.
Zurück zum Zitat Kim DH, Koo DW, Jung KE, Lee JS. An eczematous drug eruption caused by methylsulfonylmethane. Australas J Dermatol. 2016;57:e149–50.PubMed Kim DH, Koo DW, Jung KE, Lee JS. An eczematous drug eruption caused by methylsulfonylmethane. Australas J Dermatol. 2016;57:e149–50.PubMed
136.
Zurück zum Zitat Winnicki M, Shear NH. A systematic approach to systemic contact dermatitis and symmetric drug-related intertriginous and flexural exanthema (SDRIFE): a closer look at these conditions and an approach to intertriginous eruptions. Am J Clin Dermatol. 2011;12:171–80.PubMed Winnicki M, Shear NH. A systematic approach to systemic contact dermatitis and symmetric drug-related intertriginous and flexural exanthema (SDRIFE): a closer look at these conditions and an approach to intertriginous eruptions. Am J Clin Dermatol. 2011;12:171–80.PubMed
137.
Zurück zum Zitat Aquino M, Rosner G. Systemic contact dermatitis. Clin Rev Allergy Immunol. 2019;56:9–18.PubMed Aquino M, Rosner G. Systemic contact dermatitis. Clin Rev Allergy Immunol. 2019;56:9–18.PubMed
138.
Zurück zum Zitat Veien NK. Systemic contact dermatitis. Int J Dermatol. 2011;50:1445–56.PubMed Veien NK. Systemic contact dermatitis. Int J Dermatol. 2011;50:1445–56.PubMed
139.
Zurück zum Zitat Angelini G, Vena GA, Grandolfo M, Mastrolonardo M. Iatrogenic contact dermatitis and eczematous reactions. Clin Dermatol. 1993;11:467–77.PubMed Angelini G, Vena GA, Grandolfo M, Mastrolonardo M. Iatrogenic contact dermatitis and eczematous reactions. Clin Dermatol. 1993;11:467–77.PubMed
140.
Zurück zum Zitat Fowler JF. Systemic contact dermatitis caused by oral chromium picolinate. Cutis. 2000;65:116.PubMed Fowler JF. Systemic contact dermatitis caused by oral chromium picolinate. Cutis. 2000;65:116.PubMed
141.
Zurück zum Zitat Skog E. Systemic eczematous contact-type dermatitis induced by iodochlorhydroxyquin and chloroquine phosphate. Contact Dermat. 1975;1:187. Skog E. Systemic eczematous contact-type dermatitis induced by iodochlorhydroxyquin and chloroquine phosphate. Contact Dermat. 1975;1:187.
142.
Zurück zum Zitat Özkaya E, Topkarci Z, Özarmaǧan G. Systemic allergic dermatitis from chromium in a multivitamin/multimineral tablet. Contact Dermat. 2010;62:184. Özkaya E, Topkarci Z, Özarmaǧan G. Systemic allergic dermatitis from chromium in a multivitamin/multimineral tablet. Contact Dermat. 2010;62:184.
143.
Zurück zum Zitat Lawrence CM, Byrne JPH. Eczematous eruption from oral diphenhydramine. Contact Dermat. 1981;7:276–7. Lawrence CM, Byrne JPH. Eczematous eruption from oral diphenhydramine. Contact Dermat. 1981;7:276–7.
144.
Zurück zum Zitat Poon E, Fewings JM. Generalized eczematous reaction to budesonide in a nasal spray with cross-reactivity to triamcinolone. Australas J Dermatol. 2001;42:36–7.PubMed Poon E, Fewings JM. Generalized eczematous reaction to budesonide in a nasal spray with cross-reactivity to triamcinolone. Australas J Dermatol. 2001;42:36–7.PubMed
145.
Zurück zum Zitat Tomb RR, Lepoittevin J-P, Espinassouze F, Heid E, Foussereau J. Systemic contact dermatitis from pseudoephedrine. Contact Dermat. 1991;24:86–8. Tomb RR, Lepoittevin J-P, Espinassouze F, Heid E, Foussereau J. Systemic contact dermatitis from pseudoephedrine. Contact Dermat. 1991;24:86–8.
146.
Zurück zum Zitat Miyahara A, Kawashima H, Okubo Y, Hoshika A. A new proposal for a clinical-oriented subclassification of baboon syndrome and a review of baboon syndrome. Asian Pac J Allergy Immunol. 2011;29:150–60.PubMed Miyahara A, Kawashima H, Okubo Y, Hoshika A. A new proposal for a clinical-oriented subclassification of baboon syndrome and a review of baboon syndrome. Asian Pac J Allergy Immunol. 2011;29:150–60.PubMed
147.
Zurück zum Zitat Häusermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermat. 2004;51:297–310. Häusermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermat. 2004;51:297–310.
148.
Zurück zum Zitat Lachapelle J-M, Maibach HI. Patch testing and prick testing: a practical guide official publication of the ICDRG. 4th ed. Cham: Springer; 2020. Lachapelle J-M, Maibach HI. Patch testing and prick testing: a practical guide official publication of the ICDRG. 4th ed. Cham: Springer; 2020.
149.
Zurück zum Zitat White CR. Histopathology of exogenous and systemic contact eczema. Semin Dermatol. 1990;9:226–9.PubMed White CR. Histopathology of exogenous and systemic contact eczema. Semin Dermatol. 1990;9:226–9.PubMed
150.
Zurück zum Zitat Özkaya E, Yazganoğlu KD. General aspects of adverse cutaneous drug reactions. In: Özkaya E, Yazganoğlu KD, editors. Adverse cutaneous drug reactions to cardiovascular drugs. London: Springer; 2014. p. 3–63. Özkaya E, Yazganoğlu KD. General aspects of adverse cutaneous drug reactions. In: Özkaya E, Yazganoğlu KD, editors. Adverse cutaneous drug reactions to cardiovascular drugs. London: Springer; 2014. p. 3–63.
151.
Zurück zum Zitat Jensen CS, Lisby S, Larsen JK, Veien NK, Menné T. Characterization of lymphocyte subpopulations and cytokine profiles in peripheral blood of nickel-sensitive individuals with systemic contact dermatitis after oral nickel exposure. Contact Dermat. 2004;50:31–8. Jensen CS, Lisby S, Larsen JK, Veien NK, Menné T. Characterization of lymphocyte subpopulations and cytokine profiles in peripheral blood of nickel-sensitive individuals with systemic contact dermatitis after oral nickel exposure. Contact Dermat. 2004;50:31–8.
152.
Zurück zum Zitat Michel M, Dompmartin A, Szczurko C, Casttel B, Moreau A, Leroy D. Eczematous-like drug eruption induced by synergistins. Contact Dermat. 1996;34:86–7. Michel M, Dompmartin A, Szczurko C, Casttel B, Moreau A, Leroy D. Eczematous-like drug eruption induced by synergistins. Contact Dermat. 1996;34:86–7.
153.
Zurück zum Zitat Goossens C, Sass U, Song M. Baboon syndrome. Dermatology. 1997;194:421–2.PubMed Goossens C, Sass U, Song M. Baboon syndrome. Dermatology. 1997;194:421–2.PubMed
154.
Zurück zum Zitat Ash S, Scheman AJ. Systemic contact dermatitis to hydroxyzine. Am J Contact Dermat. 1997;8:2–5.PubMed Ash S, Scheman AJ. Systemic contact dermatitis to hydroxyzine. Am J Contact Dermat. 1997;8:2–5.PubMed
155.
Zurück zum Zitat Reid N, Jariwala S, Hudes G, Fodeman J, Jerschow E, Rosenstreich D. Worsening of contact dermatitis by oral hydroxyzine: a case report. Dermatol Online J. 2013;19:4.PubMed Reid N, Jariwala S, Hudes G, Fodeman J, Jerschow E, Rosenstreich D. Worsening of contact dermatitis by oral hydroxyzine: a case report. Dermatol Online J. 2013;19:4.PubMed
156.
Zurück zum Zitat Browne F, Wilkinson SM. Effective prescribing in steroid allergy: controversies and cross-reactions. Clin Dermatol. 2011;29:287–94.PubMed Browne F, Wilkinson SM. Effective prescribing in steroid allergy: controversies and cross-reactions. Clin Dermatol. 2011;29:287–94.PubMed
157.
Zurück zum Zitat Bircher AJ, Bigliardi P, Zaugg T, Mäkinen-Kiljunen S. Delayed generalized allergic reactions to corticosteroids. Dermatol Basel Switz. 2000;200:349–51. Bircher AJ, Bigliardi P, Zaugg T, Mäkinen-Kiljunen S. Delayed generalized allergic reactions to corticosteroids. Dermatol Basel Switz. 2000;200:349–51.
158.
Zurück zum Zitat Lauerma AI, Reitamo S, Maibach HI. Systemic hydrocortisone/cortisol induces allergic skin reactions in presensitized subjects. J Am Acad Dermatol. 1991;24:182–5.PubMed Lauerma AI, Reitamo S, Maibach HI. Systemic hydrocortisone/cortisol induces allergic skin reactions in presensitized subjects. J Am Acad Dermatol. 1991;24:182–5.PubMed
159.
Zurück zum Zitat Baeck M, Chemelle JA, Goossens A, Nicolas JF, Terreux R. Corticosteroid cross-reactivity: clinical and molecular modelling tools. Allergy. 2011;66:1367–74.PubMed Baeck M, Chemelle JA, Goossens A, Nicolas JF, Terreux R. Corticosteroid cross-reactivity: clinical and molecular modelling tools. Allergy. 2011;66:1367–74.PubMed
160.
Zurück zum Zitat Hindson C. Contact eczema from methyl salicylate reproduced by oral aspirin (acetyl salicylic acid). Contact Dermat. 1977;3:348–9. Hindson C. Contact eczema from methyl salicylate reproduced by oral aspirin (acetyl salicylic acid). Contact Dermat. 1977;3:348–9.
161.
Zurück zum Zitat Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Risk of skin reactions when using ibuprofen-based medicines. Expert Opin Drug Saf. 2005;4:837–48.PubMed Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Risk of skin reactions when using ibuprofen-based medicines. Expert Opin Drug Saf. 2005;4:837–48.PubMed
162.
Zurück zum Zitat Lakshmi C, Srinivas CR. Systemic (allergic) contact dermatitis to diclofenac. Indian J Dermatol Venereol Leprol. 2011;77:536.PubMed Lakshmi C, Srinivas CR. Systemic (allergic) contact dermatitis to diclofenac. Indian J Dermatol Venereol Leprol. 2011;77:536.PubMed
163.
Zurück zum Zitat El Sayed F, Bayle-Lebey P, Marguery MC, Bazex J. Systemic sensitization to 17-beta estradiol induced by transcutaneous administration. Ann Dermatol Venereol. 1996;123:26–8.PubMed El Sayed F, Bayle-Lebey P, Marguery MC, Bazex J. Systemic sensitization to 17-beta estradiol induced by transcutaneous administration. Ann Dermatol Venereol. 1996;123:26–8.PubMed
164.
Zurück zum Zitat Jacob SE, Zapolanski T, Chayavichitsilp P. Sensitivity to para-phenylenediamine and intolerance to hydrochlorothiazide. Dermatitis. 2008;19:E44–5.PubMed Jacob SE, Zapolanski T, Chayavichitsilp P. Sensitivity to para-phenylenediamine and intolerance to hydrochlorothiazide. Dermatitis. 2008;19:E44–5.PubMed
165.
Zurück zum Zitat Malinauskiene L, Isaksson M, Bruze M. Systemic contact dermatitis in a gold-allergic patient after treatment with an oral homeopathic drug. J Am Acad Dermatol. 2013;68:e58.PubMed Malinauskiene L, Isaksson M, Bruze M. Systemic contact dermatitis in a gold-allergic patient after treatment with an oral homeopathic drug. J Am Acad Dermatol. 2013;68:e58.PubMed
166.
Zurück zum Zitat Glatz M, Hofbauer GFL. Phototoxic and photoallergic cutaneous drug reactions. In: French LE, editor. Adverse cutaneous drug eruptions. Chem Immunol Allergy. Basel: Karger; 2012. p. 167–79. Glatz M, Hofbauer GFL. Phototoxic and photoallergic cutaneous drug reactions. In: French LE, editor. Adverse cutaneous drug eruptions. Chem Immunol Allergy. Basel: Karger; 2012. p. 167–79.
167.
Zurück zum Zitat Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf. 2007;6:431–43.PubMed Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf. 2007;6:431–43.PubMed
168.
Zurück zum Zitat Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol. 1995;33:551–73.PubMed Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol. 1995;33:551–73.PubMed
169.
Zurück zum Zitat Blakely KM, Drucker AM, Rosen CF. Drug-induced photosensitivity: an update: culprit drugs, prevention and management. Drug Saf. 2019;42:827–47.PubMed Blakely KM, Drucker AM, Rosen CF. Drug-induced photosensitivity: an update: culprit drugs, prevention and management. Drug Saf. 2019;42:827–47.PubMed
170.
Zurück zum Zitat Youn JI, Lee HG, Yeo UC, Lee YS. Piroxicam photosensitivity associated with vesicular hand dermatitis. Clin Exp Dermatol. 1993;18:52–4.PubMed Youn JI, Lee HG, Yeo UC, Lee YS. Piroxicam photosensitivity associated with vesicular hand dermatitis. Clin Exp Dermatol. 1993;18:52–4.PubMed
171.
Zurück zum Zitat Ljunggren B, Hindsén M, Isaksson M. Systemic quinine photosensitivity with photoepicutaneous cross-reactivity to quinidine. Contact Dermat. 1992;26:1–4. Ljunggren B, Hindsén M, Isaksson M. Systemic quinine photosensitivity with photoepicutaneous cross-reactivity to quinidine. Contact Dermat. 1992;26:1–4.
172.
Zurück zum Zitat Wolf R, Dorfman B, Krakowski A. Quinidine-induced lichenoid and eczematous photodermatitis. Dermatology. 1987;174:285–9. Wolf R, Dorfman B, Krakowski A. Quinidine-induced lichenoid and eczematous photodermatitis. Dermatology. 1987;174:285–9.
173.
Zurück zum Zitat Lim HW, Buchness MR, Ashinoff R, Soter NA. Chronic actinic dermatitis: study of the spectrum of chronic photosensitivity in 12 patients. Arch Dermatol. 1990;126:317–23.PubMed Lim HW, Buchness MR, Ashinoff R, Soter NA. Chronic actinic dermatitis: study of the spectrum of chronic photosensitivity in 12 patients. Arch Dermatol. 1990;126:317–23.PubMed
174.
Zurück zum Zitat Braunstein BL. Dyshidrotic eczema associated with piroxicam photosensitivity. Cutis. 1985;35:485–6.PubMed Braunstein BL. Dyshidrotic eczema associated with piroxicam photosensitivity. Cutis. 1985;35:485–6.PubMed
175.
Zurück zum Zitat White IR. Photopatch test in a hydrochlorothiazide drug eruption. Contact Dermat. 1983;9:237–237. White IR. Photopatch test in a hydrochlorothiazide drug eruption. Contact Dermat. 1983;9:237–237.
176.
Zurück zum Zitat Gómez-Bernal S, Álvarez-Pérez A, Rodríguez-Pazos L, Gutiérrez-González E, Rodríguez-Granados MT, Toribio J. Photosensitivity due to thiazides. Actas Dermosifiliogr. 2012;105:359–66. Gómez-Bernal S, Álvarez-Pérez A, Rodríguez-Pazos L, Gutiérrez-González E, Rodríguez-Granados MT, Toribio J. Photosensitivity due to thiazides. Actas Dermosifiliogr. 2012;105:359–66.
177.
Zurück zum Zitat Silverberg JI. Adult-onset atopic dermatitis. J Allergy Clin Immunol Pract. 2019;7:28–33.PubMed Silverberg JI. Adult-onset atopic dermatitis. J Allergy Clin Immunol Pract. 2019;7:28–33.PubMed
178.
Zurück zum Zitat Brummer GC, Wang LT, Sontheimer RD. A possible role for dupilumab (Dupixent) in the management of idiopathic chronic eczematous eruption of aging. Dermatol Online J. 2018;24:13030/qt55z1f6xh. Brummer GC, Wang LT, Sontheimer RD. A possible role for dupilumab (Dupixent) in the management of idiopathic chronic eczematous eruption of aging. Dermatol Online J. 2018;24:13030/qt55z1f6xh.
179.
Zurück zum Zitat Chen JK, Jacob SE, Nedorost ST, Hanifin JM, Simpson EL, Boguniewicz M, et al. A pragmatic approach to patch testing atopic dermatitis patients: clinical recommendations based on expert consensus opinion. Dermatitis. 2016;27:186–92.PubMed Chen JK, Jacob SE, Nedorost ST, Hanifin JM, Simpson EL, Boguniewicz M, et al. A pragmatic approach to patch testing atopic dermatitis patients: clinical recommendations based on expert consensus opinion. Dermatitis. 2016;27:186–92.PubMed
180.
Zurück zum Zitat Silvestre Salvador JF, Romero-Pérez D, Encabo-Durán B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol. 2017;27:78–88.PubMed Silvestre Salvador JF, Romero-Pérez D, Encabo-Durán B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol. 2017;27:78–88.PubMed
181.
Zurück zum Zitat Osawa J, Naito S, Aihara M, Kitamura K, Ikezawa Z, Nakajima H. Evaluation of skin test reactions in patients with non-immediate type drug eruptions. J Dermatol. 1990;17:235–9.PubMed Osawa J, Naito S, Aihara M, Kitamura K, Ikezawa Z, Nakajima H. Evaluation of skin test reactions in patients with non-immediate type drug eruptions. J Dermatol. 1990;17:235–9.PubMed
182.
Zurück zum Zitat Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology. 2005;209:209–16.PubMed Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology. 2005;209:209–16.PubMed
183.
Zurück zum Zitat Barbaud A. Skin testing and patch testing in non-IgE-mediated drug allergy. Curr Allergy Asthma Rep. 2014;14:442.PubMed Barbaud A. Skin testing and patch testing in non-IgE-mediated drug allergy. Curr Allergy Asthma Rep. 2014;14:442.PubMed
184.
Zurück zum Zitat Wilkinson DS, Fregert S, Magnusson B, Bandmann HJ, Calnan CD, Cronin E, et al. Terminology of contact dermatitis. Acta Derm Venereol. 1970;50:287–92.PubMed Wilkinson DS, Fregert S, Magnusson B, Bandmann HJ, Calnan CD, Cronin E, et al. Terminology of contact dermatitis. Acta Derm Venereol. 1970;50:287–92.PubMed
185.
Zurück zum Zitat Popple A, Williams J, Maxwell G, Gellatly N, Dearman RJ, Kimber I. The lymphocyte transformation test in allergic contact dermatitis: new opportunities. J Immunotoxicol. 2016;13:84–91.PubMed Popple A, Williams J, Maxwell G, Gellatly N, Dearman RJ, Kimber I. The lymphocyte transformation test in allergic contact dermatitis: new opportunities. J Immunotoxicol. 2016;13:84–91.PubMed
186.
Zurück zum Zitat Stejskal VD, Olin RG, Forsbeck M. The lymphocyte transformation test for diagnosis of drug-induced occupational allergy. J Allergy Clin Immunol. 1986;77:411–26.PubMed Stejskal VD, Olin RG, Forsbeck M. The lymphocyte transformation test for diagnosis of drug-induced occupational allergy. J Allergy Clin Immunol. 1986;77:411–26.PubMed
187.
Zurück zum Zitat Spoerri I, Bircher AJ, Link S, Heijnen IAFM, Scherer HK. Delayed-type allergy to cobalt-comparison of a flow cytometric lymphocyte proliferation test with patch testing. Contact Dermat. 2018;79:31–3. Spoerri I, Bircher AJ, Link S, Heijnen IAFM, Scherer HK. Delayed-type allergy to cobalt-comparison of a flow cytometric lymphocyte proliferation test with patch testing. Contact Dermat. 2018;79:31–3.
188.
Zurück zum Zitat Dawe RS, Ibbotson SH. Drug-induced photosensitivity. Dermatol Clin. 2014;32(363–8):ix. Dawe RS, Ibbotson SH. Drug-induced photosensitivity. Dermatol Clin. 2014;32(363–8):ix.
189.
Zurück zum Zitat Ferguson J. Photosensitivity due to drugs. Photodermatol Photoimmunol Photomed. 2002;18:262–9.PubMed Ferguson J. Photosensitivity due to drugs. Photodermatol Photoimmunol Photomed. 2002;18:262–9.PubMed
190.
Zurück zum Zitat Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(10–22):e2. Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(10–22):e2.
191.
Zurück zum Zitat Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35:785–92.PubMed Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35:785–92.PubMed
Metadaten
Titel
Eczematous Drug Eruptions
verfasst von
Amy E. Blum
Susan Burgin
Publikationsdatum
15.02.2021
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 3/2021
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-021-00586-8

Weitere Artikel der Ausgabe 3/2021

American Journal of Clinical Dermatology 3/2021 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.